Abstract: This invention provides for a RSV-targeted nanoparticle PMN (RTPMN), combining HR2D anti-fusion peptide, and plasmid encoded siRNA against RSV-NS1 and/or RSV-P gene as a safe, effective and inexpensive anti-RSV prophylaxis and/or therapy.

Abstract: The present invention provides methods and materials useful delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the present invention provides methods for delivering saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The delivery methods and materials herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.

Abstract: An artificial urinary sphincter can include a cuff configured to surround a portion of a length of a urethra. An actuator is configured to selectively apply a force to the cuff to thereby apply variable amount of pressure to the urethra. A controller is configured to adjust the application of the force by the actuator to cause the cuff to apply the variable amount of pressure to the urethra. A sensor can be in communication with the controller and configured to detect pressure applied against the cuff by the urethra. The controller is configured to cause the cuff to apply a first closing pressure to the urethra. In response to a detection of a threshold pressure increase by the sensor, the controller is configured to cause the cuff to apply a second closing pressure that is greater than the first closing pressure and that prevents urine from exiting the urethra.

Abstract: Disclosed is an oxygen-containing heterocyclic compound, and use thereof. The present disclosure provides an oxygen-containing heterocyclic compound represented by Formula I, a pharmaceutically acceptable salt thereof, deuterated derivative thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof or a crystal form thereof, and the oxygen-containing heterocyclic compound is expected to selectively inhibit Smad3 activation.

Abstract: Embodiments discussed herein facilitate determination of a response to treatment and/or a prognosis for a tumor based at least in part on features of tumor-associated vasculature (TAV). One example embodiment is a method, comprising: accessing a medical imaging scan of a tumor, wherein the tumor is segmented on the medical imaging scan; segmenting tumor-associated vasculature (TAV) associated with the tumor based on the medical imaging scan; extracting one or more features from the TAV; providing the one or more features extracted from the TAV to a trained machine learning model; and receiving, from the machine learning model, one of a predicted response to a treatment for the tumor or a prognosis for the tumor.

Abstract: A MS disease activity (MSDA) score is provided as a tool to detect relapse and response to glatiramer acetate (GA) therapy in subjects having relapsing-remitting multiple sclerosis (RRMS) using the blood-based biomarkers SIRT1, RGC-32, FasL, IL-21, pSIRT1 and JNK p54.

Abstract: Provided herein are compositions, methods, kits and systems for treating cells, tissues and subjects to alter age-related biology (e.g., to study or to treat age-related diseases and conditions). In particular, provided herein are compositions, methods, and uses for inhibition or modification of sialic acid or its cognate receptor to restore phagocytosis in aged cells.

Abstract: A surgical navigation system may include a processor and a display. The processor may receive a patient image and sensor data captured by a sensor, receive a medical image, generate a hologram of the medical image, perform coregistration between the patient image and the hologram, superimpose the hologram on the patient image, and display the superimposed image. Coregistration may be performed manually via a user interaction, or automatically based on one or more fiducials in the medical image and sensor data related to the fiducials. The system may monitor a change in the environment and update the display correspondingly. For example, the system may monitor a movement of a body of the patient, monitor the size of an organ of the patient as the organ is being under operation, or a movement of the surgical instrument. The sensor may be an augmented reality (AR) sensor in an AR device.

Abstract: Disclosed are methods of decreasing cachexia in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of decreasing bone destruction in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of ameliorating one or more symptoms or side effects of breast or prostate cancer in a breast or prostate cancer patient comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of treating osteoporosis in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof.

Abstract: Pump systems for use in suspension of a prosthetic device from a residual limb and methods of suspending a prosthetic device from a residual limb are disclosed. The pump systems include a mechanically activated pump having a first compression member coupled to a second compression member, a diaphragm disposed between the first and second compression members, and coupling elements that engage and couple together the first and second compression members. The mechanically activated pump may be connected with an electrically activated pump, forming a hybrid pump system to provide vacuum engagement between a prosthetic device and a residual limb.

Abstract: A customizable headgear assembly for neuropsychological and neurological treatment, monitoring, or testing of a patient. The headgear assembly comprising a structural frame having a plurality of anatomical landmark tabs each individually configured to be located upon an anatomical landmark of a patient's head. The structural frame having first and second portions releasably coupled to enable the first and second portions to be at least partially separated for placement and removal from the patient's head. A plurality of electrode holders being operable coupled to the structural frame each configured to locate an electrode upon a predetermined neurological position of the patient.

Abstract: A guide system is provided that uses a plurality of sensors to identify and determine a clear path for an ambulatory vision impaired person. The system includes one or more wheels that rotate to propel the system, a platform supported by the one or more wheels and housing a processor, a rigid harness with a haptic feedback grip that is positioned to be grasped by an operator, and one or more sensors configured to sense information about the environment. In operation, the processor analyzes information sensed by the sensors to identify object in the path of the guide system and sends messages to the operator to allow the operator to avoid the identified objects. The messages may be sent to the operator via the haptic feedback grip or audibly via a speaker or via a wireless connection to a haptic or audio device being worn by the operator.

Abstract: Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

Abstract: This disclosure relates to topical lithium agents including inhalable lithium agents for treating a viral infection characterized by a cytokine storm in the respiratory tract of a subject such as a human. Topical lithium formulations can be used to mitigate such viral infections, including coronavirus infections.

Abstract: The present disclosure provides methods and compositions for inhibiting Wnt5a expression in cells such as prostate cancer cells.

Abstract: Provided herein are formulations that can contain an effective amount of a PKC? inhibitor. Also provided herein are methods of inhibiting a PKC? in a subject in need thereof, that can include the step of administering an effective amount of a compound that is capable of inhibiting a PKC?.

Abstract: A surgical method of cataract fragmentation and extraction via microbubble cavitation is described. In particular, gas-filled microbubbles are injected into a lens capsule of a subject's eye, and cavitation of the microbubbles is activated by applied ultrasound energy. The ultrasound energy can be applied from an external device. The cavitation fragments cataract tissues without damaging other tissue, such as the lens capsule. Fragmented lens material is then aspirated from the lens capsule. The method can be used alone or in conjunction with other methods, such as phacoemulsification.

Abstract: The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.